| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | PF-4708671 | GDSC1000 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | AG-014699 | GDSC1000 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | MK-2206 | GDSC1000 | pan-cancer | AAC | 0.0086 | 0.8 |
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | 0.0078 | 0.8 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.0074 | 0.9 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | 0.0069 | 0.9 |